Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate.
- Author:
Shan-Shan CHEN
- Publication Type:Editorial
- MeSH:
Antineoplastic Agents;
pharmacology;
therapeutic use;
Benzamides;
Clinical Trials, Phase II as Topic;
Drug Resistance, Neoplasm;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
Piperazines;
pharmacology;
therapeutic use;
Pyrimidines;
pharmacology;
therapeutic use
- From:
Chinese Journal of Hematology
2006;27(7):433-435
- CountryChina
- Language:Chinese
